Literature DB >> 1648329

Does additive radiotherapy after hilar resection improve survival of cholangiocarcinoma? An analysis in sixty-four patients.

P C Verbeek1, D J Van Leeuwen, M N Van Der Heyde, D Gonzalez Gonzalez.   

Abstract

Between September 1983 and January 1990, 64 patients with Klatskin tumors were treated with resective therapy in the Academic Medical Centre Amsterdam. Twenty-nine patients received postoperative adjuvant radiotherapy, 22 patients were treated with resective therapy only and there were 13 postoperative deaths. The longterm results in the patients treated with or without adjuvant radiotherapy were retrospectively assessed. Three patients had a curative resection. Comparison of both therapeutic modalities demonstrated a statistically significant difference in survival (P less than 0.001) in favour of the patients who were treated with additive radiotherapy. The radiotherapy was generally well tolerated.

Entities:  

Mesh:

Year:  1991        PMID: 1648329

Source DB:  PubMed          Journal:  Ann Chir        ISSN: 0003-3944


  3 in total

1.  Interleukin-2 gene-encoded stromal cells inhibit the growth of metastatic cholangiocarcinomas.

Authors:  Myung-Hwan Kim; Sang Soo Lee; Sung Koo Lee; Seung-Gyu Lee; Chul-Won Suh; Gyung-Yub Gong; Jung-Sun Park; Young-Hoon Kim; Sang-Hee Kim
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

2.  Trans-hepatic technique and intraluminal Pulsed Dose Rate (PDR-BT) brachytherapy in treatment of locally advanced bile duct and pancreas cancer.

Authors:  Janusz Skowronek; Aleksander Sowier; Paweł Skrzywanek
Journal:  J Contemp Brachytherapy       Date:  2009-07-17

3.  Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells.

Authors:  L C Pederson; S M Vickers; D J Buchsbaum; S R Kancharla; M S Mayo; D T Curiel; M A Stackhouse
Journal:  J Gastrointest Surg       Date:  1998 May-Jun       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.